Presentations

November 24, 2023

SynAct Pharma – CEO Torbjørn Bjerke comments on the recent development

October 24, 2023

Interim Report Q3 2023 – Presentation

October 3, 2023

SynAct Pharma – EXPAND Study Update

September 13, 2023

EXPAND study update

September 13, 2023

CEO Torbjørn Bjerke comments on the additional data from the Expand clinical trial – September 13, 2023

September 6, 2023

CEO Torbjørn Bjerke at Börsveckan’s Seminar (Swedish)

September 4, 2023

Presentation regarding the announced top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients

September 4, 2023

Direkt: Comment on the EXPAND top line data presented today

August 4, 2023

Interim Report Q2 2023 – Presentation

June 6, 2023

SynAct Pharma presentation at the 2023 BIO International Convention

May 30, 2023

SynAct presenting at ABGSC Life Science Summit

May 30, 2023

SynAct presenting at Biostock Life Science Summit – May 30, 2023

May 23, 2023

Torbjørn Bjerke speaks at Avanza Börsdag

May 5, 2023

Capital Markets Day 2023

April 3, 2023

Biostock: About management changes

April 3, 2023

Direkt: Changes to management

March 2023

Company presentation

February 24, 2023